{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:02:23Z","timestamp":1787770943659,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2618-1","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T08:42:18Z","timestamp":1470645738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8776-7815","authenticated-orcid":false,"given":"D.","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Azraq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Eleyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"2618_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/CAD.0b013e3280124e41","volume":"18","author":"JT Hartmann","year":"2007","unstructured":"Hartmann JT. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs. 2007;18:245\u201354. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17264755 .","journal-title":"Anticancer Drugs"},{"key":"2618_CR2","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA Graaf van der","year":"2012","unstructured":"van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879\u201386. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22595799 .","journal-title":"Lancet"},{"key":"2618_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/1568009043332718","volume":"4","author":"RD Rao","year":"2004","unstructured":"Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets. 2004;4:621\u201335. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15578919 .","journal-title":"Curr Cancer Drug Targets"},{"key":"2618_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/CAD.0b013e328312c0e5","volume":"19","author":"O Merimsky","year":"2008","unstructured":"Merimsky O, Bernstein-Molho R, Sagi-Eisenberg R. Targeting the mammalian target of rapamycin in myxoid chondrosarcoma. Anticancer Drugs. 2008;19:1019\u201321. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18827568 .","journal-title":"Anticancer Drugs"},{"key":"2618_CR5","first-page":"225","volume":"31","author":"O Merimsky","year":"2007","unstructured":"Merimsky O, Gorzalczany Y, Sagi-Eisenberg R. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol. 2007;31:225\u201332. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17549426 .","journal-title":"Int J Oncol"},{"key":"2618_CR6","first-page":"931","volume":"14","author":"O Merimsky","year":"2004","unstructured":"Merimsky O. Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation. Int J Mol Med. 2004;14:931\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15492868 .","journal-title":"Int J Mol Med"},{"key":"2618_CR7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00280-012-1968-x","volume":"70","author":"R Bernstein-Molho","year":"2012","unstructured":"Bernstein-Molho R, Kollender Y, Issakov J, Bickels J, Dadia S, Flusser G, et al. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemother Pharmacol. 2012;70:855\u201360. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23053256 .","journal-title":"Cancer Chemother Pharmacol"},{"key":"2618_CR8","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/annonc\/mdp210","volume":"20","author":"S Stacchiotti","year":"2009","unstructured":"Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009;20:1886\u201394. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19570961 .","journal-title":"Ann Oncol"},{"key":"2618_CR9","first-page":"3663","volume":"34","author":"C Benson","year":"2014","unstructured":"Benson C, Vitfell-Rasmussen J, Maruzzo M, Fisher C, Tunariu N, Mitchell S, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014;34:3663\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24982384 .","journal-title":"Anticancer Res"},{"key":"2618_CR10","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","volume":"31","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31:2485\u201392. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23715582 .","journal-title":"J Clin Oncol"},{"key":"2618_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","volume":"16","author":"G Grignani","year":"2015","unstructured":"Grignani G, Palmerini E, Ferraresi V, D\u2019Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16:98\u2013107. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25498219 .","journal-title":"Lancet Oncol"},{"key":"2618_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13569-015-0022-2","volume":"5","author":"M Maruzzo","year":"2015","unstructured":"Maruzzo M, Martin-Liberal J, Messiou C, Miah A, Thway K, Alvarado R, et al. Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. Clin Sarcoma Res. 2015;5:5. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25664166 .","journal-title":"Clin Sarcoma Res"},{"key":"2618_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-3329-4-7","volume":"4","author":"AM Frezza","year":"2014","unstructured":"Frezza AM, Benson C, Judson IR, Litiere S, Marreaud S, Sleijfer S, et al. Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. Clin Sarcoma Res. 2014;4:7. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25089183 .","journal-title":"Clin Sarcoma Res"},{"key":"2618_CR14","doi-asserted-by":"crossref","unstructured":"Kim HK, Kim SY, Lee SJ, Kang M, Kim ST, Jang J, et al. BEZ235 (PIK3\/mTOR inhibitor) OvercomesPazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. Transl Oncol. 2016;9:197\u2013202. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27267837 .","DOI":"10.1016\/j.tranon.2016.03.008"},{"key":"2618_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","volume":"23","author":"G Grignani","year":"2012","unstructured":"Grignani G, Palmerini E, Dileo P, Asaftei SD, D\u2019Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508\u201316. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21527590 .","journal-title":"Ann Oncol"},{"key":"2618_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10637-015-0238-2","volume":"33","author":"HV Rodrigues","year":"2015","unstructured":"Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, et al. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive\/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015;33:700\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25902899 .","journal-title":"Invest New Drugs"},{"key":"2618_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1634\/theoncologist.2008-0188","volume":"13","author":"S Sleijfer","year":"2008","unstructured":"Sleijfer S, van der Graaf WTA, Blay J-Y. Angiogenesis inhibition in non-GIST soft tissue sarcomas. Oncologist. 2008;13:1193\u2013200. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18987047 .","journal-title":"Oncologist"},{"key":"2618_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592\u2013603. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2874834&tool=pmcentrez&rendertype=abstract .","journal-title":"Nat Rev Cancer"},{"key":"2618_CR19","doi-asserted-by":"crossref","unstructured":"Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, et al. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. Eur J Cancer. 2014;50:3021\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25269954 .","DOI":"10.1016\/j.ejca.2014.09.004"},{"key":"2618_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","volume":"12","author":"X Wan","year":"2007","unstructured":"Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12:1007\u201318. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17766661 .","journal-title":"Oncologist"},{"key":"2618_CR21","doi-asserted-by":"publisher","first-page":"8792","DOI":"10.1038\/ncomms9792","volume":"6","author":"A Mitsuhashi","year":"2015","unstructured":"Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, et al. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun. 2015;6:8792. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26635184 .","journal-title":"Nat Commun"},{"key":"2618_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1096\/fj.01-0658com","volume":"16","author":"R Humar","year":"2002","unstructured":"Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 2002;16:771\u201380. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12039858 .","journal-title":"FASEB J"},{"key":"2618_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2014.01.027","volume":"347","author":"H Yasui","year":"2014","unstructured":"Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, et al. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001. Cancer Lett. 2014;347:114\u201322. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24491407 .","journal-title":"Cancer Lett"},{"key":"2618_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22149876 .","journal-title":"N Engl J Med"},{"key":"2618_CR25","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1074\/jbc.M807532200","volume":"284","author":"RL Yamnik","year":"2009","unstructured":"Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem. 2009;284:6361\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19112174 .","journal-title":"J Biol Chem"},{"key":"2618_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.febslet.2009.11.041","volume":"584","author":"RL Yamnik","year":"2016","unstructured":"Yamnik RL, Holz MK. mTOR\/S6K1 and MAPK\/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett. 2016;584:124\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19925796 .","journal-title":"FEBS Lett"},{"key":"2618_CR27","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1158\/1078-0432.CCR-04-2402","volume":"11","author":"A Boulay","year":"2005","unstructured":"Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O\u2019Reilly T, Evans DB, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005;11:5319\u201328. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16033851 .","journal-title":"Clin Cancer Res"},{"key":"2618_CR28","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1128\/MCB.00289-08","volume":"28","author":"J Huang","year":"2008","unstructured":"Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28:4104\u201315. Available from: http:\/\/mcb.asm.org\/content\/28\/12\/4104.full .","journal-title":"Mol Cell Biol"},{"key":"2618_CR29","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1128\/MCB.24.18.7965-7975.2004","volume":"24","author":"Y Li","year":"2004","unstructured":"Li Y, Inoki K, Guan K-L. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol. 2004;24:7965\u201375. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15340059 .","journal-title":"Mol Cell Biol"},{"key":"2618_CR30","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1200\/JCO.2006.07.3411","volume":"25","author":"RS Benjamin","year":"2007","unstructured":"Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760\u20134. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17470866 .","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-2618-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2618-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:11:28Z","timestamp":1498320688000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2618-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2618-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]},"article-number":"616"}}